Results 251 to 260 of about 61,821 (357)

Current treatment algorithm: diffuse large B cell lymphoma. [PDF]

Blood Cancer J
Ansell SM, Nowakowski GS.
europepmc   +1 more source

TNMplot: An enhanced platform for pharmacological target identification through cross‐stage and pan‐cancer gene expression analysis

British Journal of Pharmacology, Volume 183, Issue 11, Page 2648-2659, June 2026.
TNMplot.com, a web‐based platform integrating RNA‐Seq and gene‐chip data from 56,938 samples, enables differential gene expression analysis across normal, primary tumour and metastatic tissues, facilitating large‐scale transcriptomic profiling across 22 tumour types.
Áron Bartha, Balázs Győrffy
wiley   +1 more source

CAR-T and BiTE: new horizons in the treatment of rheumatic autoimmune diseases. [PDF]

Front Immunol
Li J, Guo Q, Li L, Wang J, Zhang L.
europepmc   +1 more source

AMCP Market Insights: Managed care approaches to bispecific antibodies with a focus on follicular lymphoma and diffuse large B-cell lymphoma

Bridget Flavin, Denise Wolff, Laura Rose Bobolts, Tara Graff, Kirollos S. Hanna, Ryan Haumschild, Timothy Mok, Bhavesh Shah   +7 more
openalex   +2 more sources

Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma

European Journal of Haematology, Volume 116, Issue 6, Page 797-805, June 2026.
ABSTRACT Objectives CAR‐T cell therapies such as lisocabtagene maraleucel (liso‐cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B‐cell lymphoma (LBCL). The objective of this study was to assess the cost‐effectiveness of liso‐cel compared to standard of care (SOC) to treat R/R
Catherine Thieblemont, Florian Colrat, Rahma Sellami, Marine Sivignon, Adrien Petel, Sébastien Branchoux, Gérard de Pouvourville   +6 more
wiley   +1 more source

Intraperitoneal Co-Delivery of Claudin18.2×41BB and EpCAM×CD3 Bispecific Antibodies via mRNA-LNPs Synergistically Suppresses Gastric Cancer Peritoneal Metastasis Through T Cell Co-Activation. [PDF]

Int J Nanomedicine
Che J, Guo YY, Guo L, Liu J, Li T, Fei Y.   +5 more
europepmc   +1 more source

Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy [PDF]

Xiaoqiang Kang, Yue Zhao, Hong Ling, Xiao Huang   +3 more
openalex   +1 more source

Cutaneous Toxicities Associated With Amivantamab in Patients With Non‐Small Cell Lung Cancer: A Systematic Review

International Journal of Dermatology, EarlyView.
Ioannis‐Alexios Koumprentziotis, Aikaterini Bakella, Antonis Tsimpidakis, Alexander Stratigos, Vasiliki Nikolaou   +4 more
wiley   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, Volume 116, Issue 6, Page 697-708, June 2026.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Research progress on the molecular mechanisms of PD-1 and LAG-3 synergy in regulating T cell exhaustion and immunotherapy. [PDF]

Ann Med
Li M, Duan D, Liu C, Xiong Q.
europepmc   +1 more source